BioDelivery Sciences Worldwide (BDSI) got here out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to lack of $0.10 per share a yr in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of 700%. 1 / 4 in the past, it was anticipated that this specialty pharmaceutical firm would put up a lack of $0.01 per share when it really produced earnings of $0.03, delivering a shock of 400%.
During the last 4 quarters, the corporate has surpassed consensus EPS estimates 4 occasions.
BioDelivery, which belongs to the Zacks Medical – Biomedical and Genetics business, posted revenues of $31.60 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 4.98%. This compares to year-ago revenues of $18.03 million. The corporate has topped consensus income estimates 4 occasions during the last 4 quarters.
…